Lipoprotein(a), usually written Lp(a), is a genetically determined particle that travels with LDL and drives atherosclerosis independently of every other lipid number on a standard panel. It is the inherited risk marker measured once in a lifetime for most people because it barely changes with diet, exercise or age. It is also missing from the lipid panel most annual physicals order, which means a patient can have a perfect LDL and a dangerous Lp(a) and never know it.
We test Lp(a) on every new patient as part of the first Biomarker Audit, precisely because it is the one number that changes the entire cardiovascular conversation if it is high.
- Lp(a) is set by genetics, varies up to a thousandfold between people and is not reliably lowered by lifestyle.
- Roughly 20 percent of people carry levels associated with elevated lifetime cardiovascular risk.
- Standard lipid panels do not include Lp(a), so a normal LDL says nothing about it.
- Knowing your Lp(a) changes prevention strategy more than almost any other single lab result.
What Lp(a) actually is
Lp(a) is an LDL-like particle carrying a unique protein, apolipoprotein(a), whose size varies between individuals and whose blood concentration is almost entirely genetically determined. Unlike LDL, Lp(a) is not meaningfully reduced by diet, exercise or statins. It is pro-atherogenic, pro-inflammatory and pro-thrombotic. Elevated levels independently predict coronary disease, aortic valve disease and stroke.
Why your annual panel missed it
Standard lipid panels report total cholesterol, LDL, HDL and triglycerides. Lp(a) is a separate assay that must be specifically ordered. Many health systems test it only after a cardiac event, which is the least useful possible moment. The result is a specific and common pattern we see in our practice: a patient in their forties or fifties, fit, with a normal LDL, presenting with a first cardiac event, whose Lp(a) was elevated their entire life and never measured.
We consider this a failure of the system, not of the patient. It is one of the concrete reasons we built the practice around a comprehensive quarterly panel rather than an annual screening lipid.
What a high number actually means
Elevated Lp(a) is a lifetime risk amplifier, not a life sentence. It raises the importance of every other risk factor you control: ApoB, blood pressure, HbA1c, smoking status, inflammation. The clinical strategy is aggressive control of what is controllable, because the Lp(a) itself has limited treatment options today.
| Finding | What we do with it |
|---|---|
| Lp(a) high, ApoB normal | Push ApoB target lower than population guidelines suggest. Watch Lp(a)-driven risk aggressively |
| Lp(a) high, ApoB high | Statin plus possibly ezetimibe or a PCSK9 inhibitor, since PCSK9 inhibitors also lower Lp(a) modestly |
| Lp(a) high, family history of early heart disease | Cascade screening for first-degree relatives |
| Any Lp(a), symptoms or calcification on imaging | escalate to coronary calcium scoring or CT angiography |
What actually lowers it
Lifestyle does not. Statins do not (and can raise it slightly). PCSK9 inhibitors lower it modestly. The first therapy designed specifically for elevated Lp(a), an RNA-based injection called pelacarsen, is in phase 3 trials with results expected in the next few years. Until then the clinical play is aggressive ApoB control and knowing your number so the rest of your prevention is calibrated to reality.
A real objection, named plainly: 'If nothing lowers it, why test it?' Because the entire prevention strategy changes when you know. A patient with high Lp(a) deserves a lower ApoB target, earlier imaging, cascade screening for family and a more aggressive conversation about blood pressure and glucose than a patient without it. The test is cheap, it is done once and it redirects decades of prevention. We make money when you get healthier, not when you order more tests and the quarterly Biomarker Audit that includes Lp(a) is already part of the flat $299 monthly membership.
How this fits the membership
The Cardiometabolic Optimization Membership is a flat $299 per month, two-month commitment to start at $598, cancel anytime after. It covers the physician relationship, the quarterly Biomarker Audit (which includes Lp(a), ApoB, hs-CRP, HbA1c, lipids, insulin markers and the full hormone and thyroid panel) and the clinical protocols. Medication is billed separately by the pharmacy at cost with zero markup. One flat fee for the doctor, zero markup on the medicine.
We serve patients who want clinical depth beyond normal range. A normal-range panel is designed to catch disease, not to optimize a system. If you have ever been told your labs are normal while feeling that something is off, this is the clinical posture that takes that feeling seriously.
A normal LDL says nothing about Lp(a). The one number that changes everything is the one most panels never order.
Frequently asked questions
What is a high Lp(a) level?
Common thresholds describe levels above 50 mg/dL (or above 125 nmol/L) as elevated, with risk rising continuously across the distribution. There is no single cutoff that applies to everyone, because Lp(a) interacts with ApoB, blood pressure and family history. What matters clinically is the number itself, your ApoB and whether anyone in your family had early cardiac events.
Can diet or exercise lower Lp(a)?
No, not meaningfully. Lp(a) is genetically determined and lifestyle changes have minimal effect. Statins do not lower it either and may raise it slightly. PCSK9 inhibitors lower it modestly. Targeted Lp(a)-lowering therapies are in late-stage trials. Until those arrive, the strategy is aggressive control of everything else: ApoB, blood pressure, glucose and inflammation.
Should my family members be tested?
Yes. Lp(a) is inherited in a dominant pattern, so a first-degree relative of someone with an elevated level has roughly a one in two chance of carrying it too. Cascade screening is standard practice in lipid clinics and is the reason we recommend testing siblings, children and parents once, in adulthood, when an index case is found.
Does insurance cover Lp(a) testing?
Coverage varies by plan. Many cover it once per lifetime when ordered with an appropriate diagnosis code and some plans do not cover it at all. Inside our membership the test is part of the quarterly Biomarker Audit, which is included in the flat $299 monthly fee. Additional labs beyond the quarterly cadence are billed to the patient at pass-through cost.
Is Lp(a) the same as LDL?
No. Lp(a) is an LDL-like particle carrying an additional protein, apolipoprotein(a). It is pro-atherogenic, pro-inflammatory and pro-thrombotic and it is measured by a separate assay from the standard lipid panel. A normal LDL tells you nothing about Lp(a).
Who should get tested?
Everyone once in adulthood, in our clinical view. Testing is especially important with a personal or family history of early heart disease, a normal LDL despite cardiac events in the family or an unexplained aortic valve finding. Because the number is genetically fixed, one measurement in a lifetime is generally sufficient unless therapies arrive that make rechecking useful.
Does the membership include Lp(a) testing?
Yes. Lp(a) is part of the comprehensive Biomarker Audit included in the flat $299 per month Cardiometabolic Optimization Membership, repeated every 90 days. There is no additional charge for the panel itself. Labs beyond the quarterly cadence are billed at pass-through cost.
Related guides
- Cardiometabolic Optimization: the definitive guide
- What a Biomarker Audit includes
- How GLP-1s work and what happens when they stop
- Direct primary care for cardiometabolic care
External reference: the European Atherosclerosis Society consensus statement on Lp(a) is the standard clinical reference for the thresholds and screening guidance above.
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/